EBITDA: Income before interest, taxes, depreciation and amortization.
REGENXBIO Inc. (RGNX) had EBITDA of $-80.38M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
$6.39M |
|
$-90.05M |
|
$11.07M |
|
$-4.68M |
|
$89.75M |
|
$-83.36M |
|
$-6.69M |
|
$-90.05M |
|
$-90.05M |
|
$-90.05M |
|
$-90.05M |
|
$-90.05M |
|
$-90.05M |
|
$-83.36M |
|
|
EBITDA |
$-80.38M |
52.43M |
|
52.43M |
|
$-1.72 |
|
$-1.72 |
|
| Balance Sheet Financials | |
$186.52M |
|
$101.87M |
|
$155.38M |
|
$341.89M |
|
$71.11M |
|
-- |
|
$249.70M |
|
$320.81M |
|
$21.08M |
|
$21.08M |
|
$21.08M |
|
51.62M |
|
| Cash Flow Statement Financials | |
$-76.19M |
|
$70.59M |
|
$-13.64M |
|
$36.50M |
|
$17.26M |
|
$-19.24M |
|
$8.62M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.62 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-73.22% |
|
-1303.96% |
|
-1303.96% |
|
-- |
|
-1408.59% |
|
-1408.59% |
|
$-77.42M |
|
-- |
|
-- |
|
-- |
|
0.02 |
|
-- |
|
0.64 |
|
141.31 |
|
-427.15% |
|
-427.15% |
|
-26.34% |
|
-427.15% |
|
$0.41 |
|
$-1.48 |
|
$-1.45 |
|